Physician profile
Suzanne King
NPI 1760469977
$21,143.90
in general payments reported to CMS, 2019-2025
16 companies · $700 in 2025
The $700 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $1,143 · 2021: $1,380 · 2022: $904 · 2023: $15K · 2024: $823 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $2,775 · Food and Beverage: $2,619 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,200.00 |
| Travel and Lodging | $2,774.71 |
| Food and Beverage | $2,618.80 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,884.70 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,110.16 | 2020-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $1,101.67 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $1,009.41 | 2019-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $973.99 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $694.42 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $557.86 | 2024-2025 | Auvelity |
| Lundbeck LLC | $173.61 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $155.91 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $107.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $106.51 | 2021 | |
| Corium, LLC | $103.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $101.25 | 2019-2021 | |
| Allergan, INC. | $30.53 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.96 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $11.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.